Prostate cancer is the second leading cause of cancer death in American men and 12.9% of men will be diagnosed with this disease during their lifetime. Researchers at Howard University used mPEG-PLGA (cat# AK029) from PolySciTech Division of Akina, Inc (www.polyscitech.com) to make nanoparticles loaded with brusatol and docetaxel. This research holds promise to improve prostate cancer treatment in the future. Read more: Adekiya, Tayo Alex, Madison Moore, Michael Thomas, Gabriel Lake, Tamaro Hudson, and Simeon K. Adesina. "Preparation, Optimization, and In-Vitro Evaluation of Brusatol-and Docetaxel-Loaded Nanoparticles for the Treatment of Prostate Cancer." Pharmaceutics 16, no. 1 (2024): 114. https://www.mdpi.com/1999-4923/16/1/114
“Abstract: Challenges to docetaxel use in prostate cancer treatment include several resistance mechanisms as well as toxicity. To overcome these challenges and to improve the therapeutic efficacy in heterogeneous prostate cancer, the use of multiple agents that can destroy different subpopulations of the tumor is required. Brusatol, a multitarget inhibitor, has been shown to exhibit potent anticancer activity and play an important role in drug response and chemoresistance. Thus, the combination of brusatol and docetaxel in a nanoparticle platform for the treatment of prostate cancer is expected to produce synergistic effects. In this study, we reported the development of polymeric nanoparticles for the delivery of brusatol and docetaxel in the treatment of prostate cancer. The one-factor-at-a-time method was used to screen for formulation and process variables that impacted particle size. Subsequently, factors that had modifiable effects on particle size were evaluated using a 24 full factorial statistical experimental design followed by the optimization of drug loading. The optimization of blank nanoparticles gave a formulation with a mean size of 169.1 nm ± 4.8 nm, in agreement with the predicted size of 168.333 nm. Transmission electron microscopy showed smooth spherical nanoparticles. The drug release profile showed that the encapsulated drugs were released over 24 h. Combination index data showed a synergistic interaction between the drugs. Cell cycle analysis and the evaluation of caspase activity showed differences in PC-3 and LNCaP prostate cancer cell responses to the agents. Additionally, immunoblots showed differences in survivin expression in LNCaP cells after treatment with the different agents and formulations for 24 h and 72 h. Therefore, the nanoparticles are potentially suitable for the treatment of advanced prostate cancer. keywords: prostate cancer; docetaxel; brusatol; nanoparticles; cell cycle; caspase activity; surviving.”
NEW: Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/
NEW: Ashland-TM products: https://akinainc.com/polyscitech/products/ashland/
BPR (Biotech Pharma Research) Conference (April 10, 2024, KPTC West Lafayette, IN) is a free scientific/networking conference hosted by Akina (http://bprconference.com/).
Video: https://youtu.be/SCy96Ils4PQ
No comments:
Post a Comment